Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- Presentations: 34
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP05.01-030 - CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Author(s): Martin Stuschke- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-020 - Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
Author(s): David Spigel- Abstract
Loading... -
+
EP08.01-057 - Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Author(s): Martin Reck- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-060 - How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Author(s): Giannis Mountzios- Abstract
Loading... -
+
EP08.02-098 - Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Author(s): Martin Reck- Abstract
Loading...
-
+
EP14.01 - Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
- Type: E-Poster
- Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
- Presentations: 23
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP14.01-015 - IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Author(s): Luis Paz-Ares- Abstract
Loading...
-
+
EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Presentations: 31
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP16.01-011 - PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC
Author(s): Mustafa Abdo- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 12
- Coordinates: 8/07/2022, 17:00 - 19:00, Exhibit Hall - Hall B
-
+
P1.15-05 - Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
Author(s): Martin Reck- Abstract
Loading...
-
+
ES25 - Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer
- Type: Education Session
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 9
- Moderators:Martin Reck
- Coordinates: 8/08/2022, 16:00 - 17:00, Hall C1
-
+
ES25.01 - Session Introduction
16:00 - 16:01 | Author(s): Martin Reck
- Abstract
Loading... -
+
ES25.02 - Session Introduction
16:01 - 16:02 | Author(s): Sanjay Popat
- Abstract
Loading... -
+
ES25.03 - First-Line Choice in PD-L1 Positive Patients
16:02 - 16:14 | Author(s): Filiz Oezkan
- Abstract
Loading... -
+
ES25.04 - First-Line Choice in PD-L1 Negative Patients
16:14 - 16:26 | Author(s): Delvys Rodriguez-Abreu
- Abstract
Loading... -
+
ES25.05 - Second-Line Options in Immune-Pretreated Patients
16:26 - 16:38 | Author(s): Keunchil Park
- Abstract
Loading... -
+
ES25.06 - Immunotherapy in Oncogene-Addicted NSCLC
16:38 - 16:50 | Author(s): Francesco Passiglia
- Abstract
Loading... -
+
Session Moderator
16:38 - 16:50 | Author(s): Martin Reck
- Abstract
Loading... -
+
Session Moderator
16:38 - 16:50 | Author(s): Sanjay Popat
- Abstract
Loading... -
+
ES25.07 - Live Q&A
16:50 - 17:00
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 10
- Moderators:Pilar Garrido
- Coordinates: 8/09/2022, 14:30 - 15:30, Hall C7
-
+
OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
14:32 - 14:42 | Author(s): Martin Reck
- Abstract
Loading... -
+
OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
15:02 - 15:12 | Author(s): Delvys Rodriguez-Abreu
- Abstract
Loading...
